PCSK9, the attractive molecular target for controlling and decreasing the risk of cardiovascular diseases [10], is involved in the evolution of atherosclerotic plaques, while the PCSK9 inhibitor (i-PCSK9), evolocumab, displays beneficial effects in vascular function [11]. The gene discussed is PCSK9; the disease is cardiovascular disorder.